Physician profile
John Joseph Brummer
NPI 1437192457
$35,416.13
in general payments reported to CMS, 2019-2025
41 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 82% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,692 · 2020: $3,794 · 2021: $12K · 2022: $5,231 · 2023: $1,857 · 2024: $2,588 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293 · Consulting Fee: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.31 |
| Consulting Fee | $1,999.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17,868.80 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $2,558.01 | 2019-2024 | Neo-Synalar, Ketodan, Genadur |
| Zimmer Biomet Holdings, INC. | $1,577.82 | 2019 | |
| Paragon 28, INC. | $1,545.41 | 2021-2022 | |
| Stryker Corporation | $1,307.15 | 2023-2025 | Variax, Gravity, Prostep Mica |
| Medtronic, INC. | $1,189.70 | 2022-2025 | Intellis Adaptivestim |
| Bolton Medical INC | $1,140.82 | 2019-2021 | |
| Polynovo North America LLC | $899.29 | 2024-2025 | Novosorb Btm |
| Orthofix Medical, INC. | $841.05 | 2019-2023 | Physio-Stim |
| Abbott Laboratories | $730.92 | 2019-2024 | Supera |
| Paratek Pharmaceuticals, INC. | $591.66 | 2021-2023 | Nuzyra |
| Amgen INC. | $587.36 | 2025 | Krystexxa |
| Horizon Therapeutics Plc | $443.00 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $390.52 | 2022 | |
| Kerecis Limited | $369.46 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $337.82 | 2019-2023 | Puraply |
| Nevro Corp. | $315.36 | 2022 | |
| Becton, Dickinson and Company | $299.92 | 2024 | |
| Pfizer INC. | $274.65 | 2019-2020 | |
| Zyla Life Sciences, INC. | $242.93 | 2019-2020 | |
| Integra Lifesciences Corporation | $208.23 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Bioventus LLC | $206.36 | 2025 | Exogen Ultrasound Bone Healing System |
| Advanced Oxygen Therapy INC. | $148.36 | 2019 | |
| Merck Sharp & Dohme LLC | $143.75 | 2019 | |
| Acera Surgical, INC. | $129.56 | 2024 | Restrata Wound Matrix |
| Sebela Pharmaceuticals INC. | $129.46 | 2019-2023 | Pramosone, Naftin |
| Endologix LLC | $123.40 | 2025 | Torus Stent Graft System, Endocross Device |
| Celularity INC. | $111.93 | 2020 | |
| Treace Medical Concepts, INC. | $109.09 | 2022-2024 | |
| Medtronic Vascular, INC. | $105.84 | 2020 | |
| Novastep INC. | $105.43 | 2024 | Nexis |
| Smith+Nephew, INC. | $95.65 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $73.95 | 2022-2023 | Seglentis |
| Angiodynamics, INC. | $72.33 | 2023 | Auryon Laser System 100-120 Vac |
| Glenmark Therapeutics INC. | $38.00 | 2019 | |
| Polarityte, INC. | $24.29 | 2019 | |
| Endo Pharmaceuticals INC. | $18.06 | 2019 | |
| Janssen Biotech, INC. | $18.04 | 2019 | |
| Arteriocyte Medical Systems, INC. | $16.32 | 2019 | |
| Lilly USA, LLC | $15.53 | 2019 | |
| Forte Bio-Pharma LLC | $10.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$90,865.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.